NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

Core Insights - NeOnc Technologies Holdings, Inc. is expanding its operations into the Middle East through strategic partnerships and governance enhancements [1][2][3] Group 1: Strategic Developments - NeOnc's subsidiary, NuroMENA Holdings Ltd., has signed a Master Services Agreement (MSA) with Insights Research Organization and Solutions (IROS), enhancing its clinical development capabilities [1][3] - The partnership with IROS, part of the M42 group, provides access to a world-class health ecosystem, facilitating accelerated clinical trials for NeOnc's cancer therapies [3][5] - NuroMENA is expanding its Board of Directors to include key partners from Quazar Investment, aiming to strengthen regional governance and growth [2][4] Group 2: Leadership and Governance - The new board members include Waleed K. Al Ali, CEO of Quazar Investment, enhancing the leadership team overseeing NuroMENA's regional strategy [4] - The board will work alongside existing directors to establish a strong foundation for operational excellence and strategic leadership in the Middle East [5] Group 3: Clinical and Research Capabilities - IROS is recognized for its commitment to advancing clinical research and real-world evidence, leveraging cutting-edge technologies to drive innovation [6][7] - The partnership with IROS is expected to enable NeOnc to conduct clinical trials with exceptional speed, quality, and integrity, positioning Abu Dhabi as a global hub for oncology innovation [5][6] Group 4: Company Background - NeOnc Technologies is focused on developing therapies for central nervous system cancers, with its NEO™ drug development platform producing novel drug candidates [11] - The company’s therapeutics, NEO100™ and NEO212™, are currently in Phase II clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [11]